Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Lung Neoplasms 1

Interventions

Cisplatin 4atezolizumab 2Topotecan 2Paclitaxel 2Nivolumab 2Etoposide 2veliparib 1tocilizumab 1tislelizumab 1temsirolimus 1surufatinib 1sargramostim 1pentetreotide 1pembrolizumab 1niraparib 1iadademstat 1entinostat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × EC regimen × Endocrine × Clear all
NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting
203 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡